Jan 09, 2020 6:30am EST ProMIS Neurosciences to present at Sachs 3rd Annual Neuroscience Innovation Forum
Jan 08, 2020 6:30am EST ProMIS Neurosciences issues Chairman’s Update detailing positive outlook for Alzheimer’s disease therapy, pipeline in 2020
Dec 10, 2019 7:30am EST ProMIS Neurosciences’ Alzheimer’s disease program takes on renewed significance following positive aducanumab news
Dec 05, 2019 12:50pm EST Aducanumab is good; next generation Alzheimer’s disease therapies will be better
Nov 07, 2019 7:30am EST ProMIS Neurosciences Outlines Best-in-class Approach to Amyloid-beta-targeting Drug Candidates for Alzheimer’s Disease
Nov 07, 2019 7:30am EST ProMIS Neurosciences outlines best-in-class approach to amyloid-beta-targeting drug candidates for Alzheimer's disease